Ashok Leyland Regulatory Approval

Ashok Leyland Acquisition

Ashok Leyland announced NCLT Mumbai sanctioned the merger of its material subsidiary Hinduja Leyland Finance into NDL Ventures on November 3, 2026. NDL becomes the material listed subsidiary once the scheme takes effect.

Ashok Leyland Board Meeting Date

Ashok Leyland will hold a board meeting on 14 November 2026 to approve unaudited quarterly and half-year results. The trading window closes from 01 October 2026.

Ashok Leyland Business Update

Ashok Leyland reported October 2026 total vehicle sales of 21,888 units including exports, up 23% year-on-year. Domestic sales rose 24% to 20,224 units.

Ashok Leyland Management Change

Ashok Leyland announced the resignation of Mr. Raja Radhakrishnan, Head - Special Projects, from the position of Senior Management Personnel, effective October 21, 2026.

Ashok Leyland Other Announcement

Ashok Leyland Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI LODR regulations.

Ashok Leyland Debt & Borrowing: ₹500 Cr

Ashok Leyland submitted its half-yearly statement of outstanding non-convertible debentures as of September 30, 2026, as required by SEBI regulations.

Value

₹500.0 Cr

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.